The AllianceBernstein Global High Income Fund offers a 7.41% yield, higher than most fixed-income indices, making it ...

Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ETCompany ParticipantsRalf Esper - Investor RelationsBryan Kitchen ...

Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...

Sensor and Data Collection ADAS/AD relies heavily on perception sensors like cameras, radars, LiDARs, ultrasonics, and, more ...

Q1 2025 Earnings Call Transcript May 6, 2025 Evotec SE beats earnings expectations. Reported EPS is $-0.05152, expectations ...

First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts ...

Rapport Therapeutics, Inc. RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the first quarter ended March 31, 2025, and ...

And as capital becomes more politicized, inflation more entrenched, and traditional reserves more correlated, Bitcoin’s differentiated profile becomes not just defensible—but strategically necessary.

Collegium Pharmaceutical Inc. (COLL) reported robust financial results for the first quarter of 2025, with net product revenues reaching $177.8 million, marking a 23% year-over-year increase.

A comprehensive map of aberrant hematopoiesis in people with acute myeloid leukemia defines specific cell states and ...

Mersana needs data to back up its claims that Emi-Le has a differentiated profile that will meaningfully benefit patients. B7-H4 is a competitive field, with AstraZeneca, BeiGene and GSK among the ...